On October 24, 2025, Orchestra BioMed Holdings, Inc. terminated its Distribution Agreement with Terumo, granting them a right of first refusal for a $10 million fee, while also entering into a stock purchase agreement for 200,000 shares at $100 each, resulting in $20 million in gross proceeds.